January 4, 2024 – “Our relationship with OraSure is a significant milestone for Sapphiros, and we are excited to partner with an organization that shares our focus on expanding access to diagnostic insights. We believe OraSure’s existing commercial infrastructure will allow us to quickly and efficiently scale following regulatory approvals to the populations that need them the most,” said Mark Gladwell, President and CEO of Sapphiros. “We are looking forward to an innovation-filled future that will have a real impact on global health.”
Thursday, January 4, 2024
Sapphiros Is Pleased To Announce OraSure Technologies, Inc. Secures Strategic Distribution Rights and Invests In Sapphiros
More articles Copied!
Friday, August 18, 2023
Satio is pleased to announce a contract awarded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services to develop a novel, single-use, rapid ebolavirus diagnostic.
Tuesday, September 26, 2023
Satio is pleased to announce a $3.5 million Small Business Innovation Research (SBIR) contract awarded by the Advanced Research Projects Agency for Health (ARPA-H), National Institutes of Health, Department of Health and Human Services.
Wednesday, November 22, 2023
Sapphiros, a platform company dedicated to building the next generation of consumer diagnostic technologies, is proud to announce it has entered into a distribution agreement with Cencora, Inc., formerly AmerisourceBergen Corporation.